Kuala Lumpur's SaMD Shift: Pure Global on The Unseen ASEAN Data Hurdle. copertina

Kuala Lumpur's SaMD Shift: Pure Global on The Unseen ASEAN Data Hurdle.

Kuala Lumpur's SaMD Shift: Pure Global on The Unseen ASEAN Data Hurdle.

Ascolta gratuitamente

Vedi i dettagli del titolo

3 mesi a soli 0,99 €/mese

Dopo 3 mesi, 9,99 €/mese. Si applicano termini e condizioni.

A proposito di questo titolo

 In the second week of January 2026, Malaysia's Medical Device Authority introduced a pivotal update to its Software as a Medical Device (SaMD) regulations. This shift, while aligning Malaysia with global standards, presents immediate and complex challenges for international MedTech companies aiming to enter or remain in this key ASEAN market. This episode breaks down the critical changes, from stricter classification rules to new cybersecurity mandates. We analyze the real-world impact on device manufacturers, particularly the new, challenging requirements for clinical data from local populations, which could delay market entry by more than a year. **Case Study:** Imagine a promising German health-tech firm, ready to launch their AI-powered diagnostic app across Southeast Asia. They saw Malaysia as their gateway. But with the new regulations, their existing clinical data from Europe is suddenly insufficient. They now face a critical decision: invest in a costly, time-consuming local trial or pull back from the region entirely. This is the exact pain point we dissect. **Key Takeaways:** * What specific clause in the new MDA circular is catching foreign SaMD developers off guard? * Why is your existing CE or FDA approval no longer a golden ticket for the Malaysian market? * How can you determine if your "wellness app" is now considered a regulated medical device? * What are the three new cybersecurity requirements you absolutely cannot ignore? * Are there efficient strategies for gathering ASEAN-specific clinical data without a full-blown trial? * How does Malaysia's new framework compare to Singapore's or Thailand's? * What post-market surveillance activities are now mandatory for SaMDs? * Can AI tools help accelerate the compilation of the new technical dossier? At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise with advanced AI tools to streamline your global market access. Let us help you navigate the complexities of the ASEAN regulatory landscape. Contact us at info@pureglobal.com or visit https://pureglobal.com/.
Ancora nessuna recensione